vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and MetroCity Bankshares, Inc. (MCBS). Click either name above to swap in a different company.
MetroCity Bankshares, Inc. is the larger business by last-quarter revenue ($43.7M vs $34.1M, roughly 1.3× Karyopharm Therapeutics Inc.). MetroCity Bankshares, Inc. runs the higher net margin — 50.5% vs -299.9%, a 350.4% gap on every dollar of revenue. On growth, MetroCity Bankshares, Inc. posted the faster year-over-year revenue change (23.6% vs 11.6%). Over the past eight quarters, MetroCity Bankshares, Inc.'s revenue compounded faster (15.7% CAGR vs 1.4%).
Metro City Bank is a Korean-American bank based in Doraville, Georgia and offers personal and commercial banking services. It is the largest Korean-American bank to not be based out of Los Angeles, California. It currently operates a total of 19 branches in Texas, New York, New Jersey, Virginia, Georgia, Alabama, and Florida.
KPTI vs MCBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $43.7M |
| Net Profit | $-102.2M | $18.1M |
| Gross Margin | — | — |
| Operating Margin | -52.4% | 52.8% |
| Net Margin | -299.9% | 50.5% |
| Revenue YoY | 11.6% | 23.6% |
| Net Profit YoY | -232.0% | 11.7% |
| EPS (diluted) | $-7.02 | $0.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $43.7M | ||
| Q3 25 | $44.0M | $38.0M | ||
| Q2 25 | $37.9M | $37.9M | ||
| Q1 25 | $30.0M | $36.0M | ||
| Q4 24 | $30.5M | $35.4M | ||
| Q3 24 | $38.8M | $36.9M | ||
| Q2 24 | $42.8M | $36.3M | ||
| Q1 24 | $33.1M | $32.7M |
| Q4 25 | $-102.2M | $18.1M | ||
| Q3 25 | $-33.1M | $17.3M | ||
| Q2 25 | $-37.3M | $16.8M | ||
| Q1 25 | $-23.5M | $16.3M | ||
| Q4 24 | $-30.8M | $16.2M | ||
| Q3 24 | $-32.1M | $16.7M | ||
| Q2 24 | $23.8M | $16.9M | ||
| Q1 24 | $-37.4M | $14.6M |
| Q4 25 | -52.4% | 52.8% | ||
| Q3 25 | -34.6% | 62.8% | ||
| Q2 25 | -64.3% | 62.4% | ||
| Q1 25 | -110.8% | 61.3% | ||
| Q4 24 | -102.4% | 58.9% | ||
| Q3 24 | -67.8% | 61.4% | ||
| Q2 24 | -65.7% | 64.4% | ||
| Q1 24 | -101.9% | 62.6% |
| Q4 25 | -299.9% | 50.5% | ||
| Q3 25 | -75.2% | 45.5% | ||
| Q2 25 | -98.2% | 44.4% | ||
| Q1 25 | -78.2% | 45.3% | ||
| Q4 24 | -100.8% | 54.0% | ||
| Q3 24 | -82.7% | 45.3% | ||
| Q2 24 | 55.6% | 46.7% | ||
| Q1 24 | -112.8% | 44.8% |
| Q4 25 | $-7.02 | $0.69 | ||
| Q3 25 | $-3.82 | $0.67 | ||
| Q2 25 | $-4.32 | $0.65 | ||
| Q1 25 | $-2.77 | $0.63 | ||
| Q4 24 | $-2.33 | $0.64 | ||
| Q3 24 | $-3.85 | $0.65 | ||
| Q2 24 | $-2.97 | $0.66 | ||
| Q1 24 | $-4.85 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $383.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $544.2M |
| Total Assets | $108.4M | $4.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $383.7M | ||
| Q3 25 | $37.7M | $227.2M | ||
| Q2 25 | $38.7M | $286.0M | ||
| Q1 25 | $38.8M | $285.1M | ||
| Q4 24 | $62.5M | $249.9M | ||
| Q3 24 | $72.8M | $291.2M | ||
| Q2 24 | $84.8M | $327.9M | ||
| Q1 24 | $30.6M | $258.8M |
| Q4 25 | $-292.9M | $544.2M | ||
| Q3 25 | $-269.3M | $445.9M | ||
| Q2 25 | $-238.9M | $436.1M | ||
| Q1 25 | $-205.9M | $428.0M | ||
| Q4 24 | $-186.0M | $421.4M | ||
| Q3 24 | $-159.6M | $407.2M | ||
| Q2 24 | $-132.1M | $407.2M | ||
| Q1 24 | $-169.0M | $396.6M |
| Q4 25 | $108.4M | $4.8B | ||
| Q3 25 | $96.2M | $3.6B | ||
| Q2 25 | $104.9M | $3.6B | ||
| Q1 25 | $127.7M | $3.7B | ||
| Q4 24 | $164.4M | $3.6B | ||
| Q3 24 | $189.5M | $3.6B | ||
| Q2 24 | $214.0M | $3.6B | ||
| Q1 24 | $204.5M | $3.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $37.7M |
| Free Cash FlowOCF − Capex | — | $37.0M |
| FCF MarginFCF / Revenue | — | 84.7% |
| Capex IntensityCapex / Revenue | 0.0% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 2.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | $79.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $37.7M | ||
| Q3 25 | $-5.9M | $16.5M | ||
| Q2 25 | $-18.7M | $14.5M | ||
| Q1 25 | $-39.0M | $11.9M | ||
| Q4 24 | $-25.8M | $63.5M | ||
| Q3 24 | $-19.5M | $-11.5M | ||
| Q2 24 | $-38.5M | $19.4M | ||
| Q1 24 | $-43.7M | $36.4M |
| Q4 25 | — | $37.0M | ||
| Q3 25 | — | $16.2M | ||
| Q2 25 | — | $14.3M | ||
| Q1 25 | — | $11.8M | ||
| Q4 24 | $-25.9M | $62.2M | ||
| Q3 24 | — | $-11.8M | ||
| Q2 24 | — | $19.0M | ||
| Q1 24 | $-43.9M | $36.1M |
| Q4 25 | — | 84.7% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 37.8% | ||
| Q1 25 | — | 32.9% | ||
| Q4 24 | -84.7% | 175.8% | ||
| Q3 24 | — | -31.9% | ||
| Q2 24 | — | 52.4% | ||
| Q1 24 | -132.6% | 110.6% |
| Q4 25 | 0.0% | 1.5% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.2% | 3.6% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 1.0% | ||
| Q1 24 | 0.6% | 0.7% |
| Q4 25 | — | 2.08× | ||
| Q3 25 | — | 0.95× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 3.91× | ||
| Q3 24 | — | -0.69× | ||
| Q2 24 | -1.62× | 1.14× | ||
| Q1 24 | — | 2.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
MCBS
Segment breakdown not available.
